Raymond James
37th Annual Institutional Investors Conference

Tom Pike
CEO

March 7, 2016

NYSE: Q

Forward Looking Statements and Use of Non-GAAP Financial Measures

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements reflect, among other things, the Company's current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, market trends or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "should," "guidance," "targets," "will" and the negative thereof and similar words and expressions are intended to identify forward-looking statements. Actual results may differ materially from the Company's expectations due to a number of factors, including, but not limited to, that most of the Company's contracts may be terminated on short notice, and that the Company may be unable to maintain large customer contracts or to enter into new contracts; the Company may under-price its contracts, overrun its cost estimates, or fail to receive approval for or experience delays in documenting change orders; the historical indications of the relationship of backlog to revenues may not be indicative of their future relationship; the Company may be unable to maintain information systems or effectively update them; customer or therapeutic concentration could harm the Company's business; the Company's business is subject to risks associated with international operations, including economic, political and other risks such as compliance with a myriad of laws and regulations, complications from conducting clinical trials in multiple countries simultaneously and changes in exchange rates; the Company may be unable to successfully identify, acquire and integrate businesses, services and technologies; the Company's effective income tax rate may fluctuate, which may adversely affect our operations, earnings, and earnings per share; certain of the Company's corporate governance documents could make an acquisition of the Company more difficult; and the Company has substantial indebtedness and may incur additional indebtedness in the future, which could adversely affect the Company's financial condition. For a further discussion of the risks relating to the Company's business, see the "Risk Factors" in Quintiles' annual report on Form 10-K for the fiscal year ended December 31, 2015, filed with the SEC, as such factors may be amended or updated from time to time in Quintiles' subsequent periodic filings with the SEC, which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in Quintiles' filings with the SEC. The Company assumes no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.

This presentation includes financial measures not prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). Management believes that these non-GAAP financial measures provide useful supplemental information to management and investors regarding the underlying performance of the Company's business operations and are more indicative of core operating results as they exclude certain items whose fluctuations from period-to-period do not necessarily correspond to changes in the core operations of the Company's business. Investors and potential investors are encouraged to review the reconciliations of the non-GAAP financial measures to their most directly comparable GAAP measures attached to this presentation.

Enterprise Vision and Strategy

Quintiles Vision

We bring people and knowledge together for a healthier world.

Biopharma Product Development

Our Customer Promise

Improve your probability *of success*™

Integrated Healthcare Services

Excellence at Global People, Process & Technology

Scientific, Therapeutic & Rx Experience

Quantitative & Analytical Expertise

QUINTILES®

Attractive and Growing Market

~$200bn total market across both segments with increasing outsourcing penetration which drives estimated growth of 6% – 8% per year from 2015 – 2018

Approval

Phase I	Phase II	Phase III	Phase IV	Commercial	Healthcare Delivery

Product Development Services *(~74% of Quintiles' Revenues)* (1)	**Integrated Healthcare Services ('IHS')** *(~26% of Quintiles' Revenues)* (1)

$97bn Product Development Market(2)



$101bn Integrated Healthcare Services Market(2,3)



(1) For the year ended December 31, 2015
(2) Based on Company estimates.
(3) Includes market access, reimbursement, observational studies, comparative effectiveness research, health economics & outcomes research, and commercial consulting

QUINTILES

Deep Therapeutic, Domain, & Regulatory Expertise Across Fast-Growing Therapy Areas

Our resources provide competitive advantage, breadth of offerings, & ability to innovate

Apply knowledge & services across therapy areas | **Ability to serve the diverse needs of our biopharma customers**

Therapeutic Centers of Excellence



- **>10 sole-source relationships** across large, mid, and small biopharma
- Helped develop or commercialize **98 of the top 100** best-selling products of 2014
  - > All of **Top 30 Oncology products**
  - > All of **Top 30 CNS products**
- **>1,000 oncology studies** in 82 countries[(1)]
- **>375 pediatric studies** in 81 countries[(1)]
- **>230 rare disease studies** in 70 countries[(1)]
- **Market access for >150 products** in the US since 2003
- A **mid-sized pharma company entered two new therapeutic areas** and in-licensed new assets

(1) Study experience since 2010.

QUINTILES

Quintiles' Global Delivery Network (GDN) Extends Our Industry Leadership Position

Strategically leverages our global presence… …and drives quality, efficiency, & productivity



>5,100 Employees
At 7 locations in 5 countries

Centrally-managed
For process consistency & standardization

Operates as 'one'
In a virtual, coordinated manner

- **Source top talent** around the world
- **Strategically manage** peaks and troughs of supply and demand in key nodes
- **Standardize processes**, industrialized methods, tools, and architectures
- **Accelerate best practices** globally
- Implement innovative technology solutions to **automate commodity tasks**

Integrated Data Assets Combine Our Deep Expertise and Global Scale

Data Integration is key to unlocking the productivity puzzle



Access to **>61M patient lives** via **Electronic Health Records** from **>175,000 providers** since 2004

Electronic Health Records

Clinical research data collected across **487 indications** in **18 therapeutic areas**

Trial and Subject Data

Data collection experience from **~5,700 studies** and **~430,000 sites** and **~1.8M participants** from protocols

Patient Communities

>3.5M enrolled members in 6 online communities, including MediGuard & ClinicalResearch.com

>298,000 clinical investigators in Quintiles' Clinical Trial Management System

~430 direct-to-patient studies in more than 30 countries since 2008

QUINTILES

Why Quintiles?

The integration of our assets creates differentiated value

Deep therapeutic, domain, & regulatory expertise

>1,100
Medical doctors

~1,050
PhDs

14
Therapeutic centers of excellence

~850
Statisticians & statistical programmers

~5,700
Protocols, since 2000

>6,700
Sales representatives

>900
Clinical educators

14,500
Tracked HTA reports from 100 agencies

Global harmonized best in class processes & workforce

>24
Prime sites

>1,200
Partner sites

>298,000
Investigators

~100
Countries serviced

>150
Risk Based Monitoring Studies (RBM) – Leader in RBM

100%
Compliance trained field resources

>220
Product launches in 20 countries in last 5 years

~9,500
Sites active in observational research

Technology & informatics

Quintiles Infosario® Platform
Planning & Design
Global Safety System
Analytics & Informatics

Genomics & Biomarkers

Digital Patient Communities
Clinicalresearch.com
Mediguard.com
"I Am More Than Lupus"

61mm
Unique Patient Records (EHR)

Quintiles Infosario® Platform

430
Direct-to-Patient projects relying on technology

Track Record of Profitable Growth and Consistency

Long-term performance underpinned with a diversified customer portfolio

Service Revenues

’11 – ’15 CAGR = 7.0%



Adjusted EBITDA[1]

’11 – ’15 CAGR = 13.7%



	2011	2012	2013	2014	2015
Margin	**14.9%**	**14.8%**	**15.9%**	**17.4%**	**18.9%**

Backlog



Net New Business Highlights

1.23x Last 12 Month Consolidated Book-to-Bill[2,3]

≥1.20x Product Development Book-to-Bill in 12 of last 13 quarters[2,3]

QUINTILES

(1) See slide 13 for the reconciliation of net income to Adjusted EBITDA.
(2) Book-to-bill calculated as NNB divided by Service Revenues.
(3) As of December 31, 2015.

2015 Financial Highlights

9.0% Constant Currency Revenue Growth[1]

- 7.2% in Product Development
- 14.0% in IHS

23.3% Diluted Adjusted EPS Growth[2]

$397M Free cash flow

$12.04B Consolidated Backlog as of 12/31/15

✓ 1.23x Book-to-bill ratio
- 1.29x in Product Development
- 1.06x in IHS

✓ Completion of $2.75B debt refinancing
- Extends maturities and lowers average cost of debt

✓ $515 million of share repurchases
- Nearly $1B returned to shareholders since IPO in May 2013

✓ $977 million cash and cash equivalents as of 12/31/15

✓ Launch of Q^2 Solutions joint venture with Quest Diagnostics

(1) See appendix slide 14.
(2) See appendix slide 15.

Quintiles

A differentiated market leader



Appendix

Adjusted EBITDA Reconciliation

Adjusted EBITDA Reconciliation					
	Year Ended December 31				
(In Thousands)	**2011**	**2012**	**2013**	**2014**	**2015**
Adjusted EBITDA:					
Net Income Attributable to Quintiles Transnational Holdings Inc.	$241,772	$177,546	$226,591	$356,383	$387,205
Interest Expense, Net	105,126	131,304	119,571	97,179	97,475
Income Tax Expense	15,105	93,364	95,965	150,056	158,989
Depreciation and Amortization	92,004	98,288	107,504	121,013	127,742
Restructuring Costs	22,116	18,741	14,071	8,988	30,752
Impairment Charges	12,295	–	–	–	2,484
Loss on Extinguishment of Debt	46,337	1,275	19,831	–	7,780
Adjustment to Estimated Contingent Consideration	–	(4,922)	(4,910)	(8,839)	6,177
Management Fees(2)	5,213	5,309	27,694	–	–
Incremental Share-based Compensation Expense(1)	2,553	13,637	–	–	–
Bonus Paid to Certain Holders of Stock Options	10,992	11,308	–	–	–
Interest Rate Swap Termination	11,630	–	–	–	–
Gain on Sale of Business Assets	(74,880)	–	–	–	–
Adjusted EBITDA	**$490,303**	**$545,850**	**$606,317**	**$724,780**	**$818,604**
% of Service Revenues	**14.9%**	**14.8%**	**15.9%**	**17.4%**	**18.9%**

(1) Incremental expense incurred for repricings of share-based awards. The amount represents only the incremental amount of share-based compensation expense incurred in the quarter that the repricing occurred.

(2) Management fees were previously paid to affiliates of certain shareholders pursuant to a management agreement. The year ended December 31, 2013 includes a $25 million fee paid in connection with the termination of the management agreement.

2015 Constant Currency Reconciliation
Service Revenues and Income from Operations

(millions of dollars)	*Three Months Ended December 31*			*Year on Year Growth*		
Consolidated	**Actual**	**Exchange Impact**	**Constant**	**Actual**	**Exchange Impact**	**Constant**
Service Revenues	$ 1,128.6	$ (35.5)	$ 1,164.1	6.1%	(3.3%)	9.4%
Income from Operations	$ 178.0	$ 11.3	$ 166.7	12.0%	7.1%	4.9%
Adjusted Income from Operations	$ 187.7	$ 10.4	$ 177.3	14.3%	6.3%	8.0%
Adjusted Income from Operations Margin	16.6%		15.2%			
Product Development						
Service Revenues	$ 845.7	$ (22.4)	$ 868.1	9.2%	(2.9%)	12.1%
Income from Operations	$ 200.0	$ 10.7	$ 189.3	19.0%	6.4%	12.6%
Income from Operations Margin	23.7%		21.8%			
Integrated Healthcare Services						
Service Revenues	$ 282.9	$ (13.1)	$ 296.0	(2.3%)	(4.5%)	2.2%
Income from Operations	$ 23.1	$ (1.3)	$ 24.4	(4.6%)	(5.3%)	0.7%
Income from Operations Margin	8.2%		8.2%			

(millions of dollars)	*Year Ended December 31*			*Year on Year Growth*		
Consolidated	**Actual**	**Exchange Impact**	**Constant**	**Actual**	**Exchange Impact**	**Constant**
Service Revenues	$ 4,326.4	$ (212.3)	$ 4,538.7	3.9%	(5.1%)	9.0%
Income from Operations	$ 646.6	$ 30.6	$ 616.0	9.5%	5.2%	4.3%
Adjusted Income from Operations	$ 679.8	$ 27.8	$ 652.0	13.4%	4.6%	8.8%
Adjusted Income from Operations Margin	15.7%		14.4%			
Product Development						
Service Revenues	$ 3,191.6	$ (129.7)	$ 3,321.3	3.0%	(4.2%)	7.2%
Income from Operations	$ 714.6	$ 33.1	$ 681.5	10.8%	5.1%	5.7%
Income from Operations Margin	22.4%		20.5%			
Integrated Healthcare Services						
Service Revenues	$ 1,134.8	$ (82.6)	$ 1,217.4	6.3%	(7.7%)	14.0%
Income from Operations	$ 84.0	$ (10.0)	$ 94.0	29.7%	(15.4%)	45.1%
Income from Operations Margin	7.4%		7.7%			

The exchange rate impacts on service revenues equals the current period service revenues at actual rates less the current period service revenues for foreign currency denominated contracts recalculated at the prior period exchange rates. The exchange rate impacts on expenses equals the current period expenses at actual rates less the current period expenses recalculated at the prior period exchange rates.

The segment detail presented above excludes general corporate and unallocated expenses, restructuring, and impairment costs.

Reconciliation of Net Income Attributable to Quintiles to Non-GAAP Adjusted Net Income and Diluted Adjusted EPS

(millions of dollars)	Three Months Ended December 31				Year Ended December 31			
	2015	EPS[1]	2014	EPS[1]	2015	EPS[1]	2014	EPS[1]
Net Income Attributable to Quintiles	**$ 104.6**	**$ 0.85**	**$ 88.4**	**$ 0.69**	**$ 387.2**	**$ 3.08**	**$ 356.4**	**$ 2.72**
Restructuring Costs	7.2	0.06	5.2	0.04	30.8	0.25	9.0	0.07
Adjustment to Estimated Contingent Consideration[2]	0.2	-	-	-	6.2	0.05	(8.8)	(0.07)
Impairment	2.5	0.02	-	-	2.5	0.02	-	-
Loss on Extinguishment of Debt	-	-	-	-	7.8	0.06	-	-
Noncontrolling Interests Effect of Non-GAAP Adjustments[3]	(0.1)	-	-	-	(2.4)	(0.02)	-	-
Tax Effect of Adjustments[4]	(2.9)	(0.02)	(1.8)	(0.01)	(13.1)	(0.10)	(3.1)	(0.02)
Non-GAAP Adjusted Net Income	**$ 111.4**	**$ 0.90**	**$ 91.8**	**$ 0.71**	**$ 418.9**	**$ 3.33**	**$ 353.4**	**$ 2.70**
Number of Diluted Shares Outstanding[5]	**123,192**		**128,626**		**125,630**		**131,083**	

[1] EPS is represented in whole dollars.

[2] Change in estimated fair value of contingent consideration on business combinations.

[3] Reflects the portion of Q[2] Solutions' after-tax non-GAAP adjustments attributable to the minority interest partner.

[4] The tax effect of adjustments was based on the income tax rate of the respective transactions, which was 38.5%, with the exception of i) restructuring costs which were tax effected at 27.6% and 34.7% during the three months ended December 31, 2015 and 2014, respectively, and 29.7% and 34.6% during the years ended December 31, 2015 and 2014, respectively and ii) contingent consideration which is not tax effected as it represents a permanent difference between book and tax income.

[5] Diluted shares are represented in thousands.

Note: Totals may not sum due to rounding; percentages are calculated from the actual results rounded to the nearest thousand.